【摘要】 中心性浆液性脉络膜视网膜病变(CSC)是60岁以下的健康男性较为常见的视网膜疾病，单眼或双眼发病，具有自限性，可反复发作，多次复发者或慢性患者具有向脉络膜新生血管(CNV)或息肉样脉络膜血管病变(PCV)转化的可能。目前的主要治疗方法为光动力治疗、阈值下微脉冲激光治疗和药物治疗等。其发病机制尚未完全知晓，但随着其病因的不断揭晓，针对CSC治疗的药物研究也越来越火热，尤其是盐皮质激素受体拮抗剂和抗血管内皮生长因子(VEGF)药物。此外，还有褪黑素、非那雄胺、幽门螺旋杆菌根除、β-受体阻滞剂等。这些药物被证明对于提高CSC患者的最佳矫正视力(BCVA)、降低黄斑中心凹厚度(CMT)或减少视网膜下积液(SRF)具有积极作用。本综述总结了目前对CSC治疗药物的研究进展，并为今后的研究方向提供一些建议。更多还原

【Abstract】 Central serous chorioretinopathy( CSC) is a common retinal disease in healthy men under 60 years of age. It occurs in one or both eyes and is self-limited and can occur repeatedly. In the case of repeated recurrence,it is possible to transform to choroidal neovascularization( CNV) or polypoid choroidal vasculopathy disease( PCV). At present,the main treatment methods are photodynamic therapy,micropulse subthreshold laser therapy and drug therapy. The pathogenesis of CSC is still not fully understood,but with the continuous discovery of its etiology,the research on drugs for the treatment of CSC is getting more and more heated,especially corticosteroid receptor antagonists and anti-vascular endothelial growth factor( VEGF) drugs. In addition,there are melatonin,finasteride,helicobacter pylorieradication,beta blockers,and so on. These drugs have been shown to have a positive effect on improving the best-corrected visual acuity( BCVA) or reducing central macular thickness( CMT) or reducing subretinal fluid( SRF) in patients with CSC. This review summarizes the current research progress of drug therapy for CSC,and provides some suggestions for future research direction.更多还原